Conditions: Metastatic Breast Cancer
Keywords: Metastatic Breast Cancer Molecular profiling
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 28
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.

Detailed description:
To determine the percent of patients with refractory breast cancer where molecular profiling and RPMA-based protein pathway activation analysis of their tumor, can change the clinical course of their disease (i.e. produce a Growth Modulation Index (GMI) ≥1.3). The GMI is calculated as the ratio of Progression-free survival (PFS) under molecular profiling and RPMA analysis selected treatment to the time to progression (TTP) for the most recent regimen the patient has progressed on.

Arms:
arm 1: Blood drawn for molecular profiling

Interventions: intervention 1: Approved therapy will be assigned based on molecular profile and RPMA results
Intervention descriptions: intervention 1: treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results

Protocol document: